Work

1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1427

Authors: I. Pires da Silva, D. Zakria, T. Ahmed, C. Trojaniello, F. Dimitriou, C. Allayous, C. Gerard, L. Zimmer, S. Lo, O.A. Michielin, C. Lebbe, J. Mangana, P.A. Ascierto, D. Johnson, M. Carlino, A.M. Menzies, G.V. Long

Institutions: Melanoma Institute Australia, Vanderbilt University Medical Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University Hospital Zurich, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Hospitalier Universitaire Vaudois, Essen University Hospital, The University of Sydney

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, AstraZeneca, Roche, Sanofi, Mount Sylvia Diatomite

OpenAlex ID: W3201979916

FWCI:

Cites:

Cited by:

Related to: 10